tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Orica Reports Cessation of 5,417 Performance Rights in Routine Capital Update

Story Highlights
  • Orica Limited reported the cessation of 5,417 ORIAB performance rights effective 31 December 2025.
  • The change represents routine adjustment to Orica’s issued capital, likely tied to equity incentive arrangements rather than major capital strategy shifts.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Orica Reports Cessation of 5,417 Performance Rights in Routine Capital Update

Claim 50% Off TipRanks Premium

Orica Limited ( (AU:ORI) ) has provided an announcement.

Orica Limited has notified the market of the cessation of 5,417 performance rights (security code ORIAB) effective 31 December 2025, as disclosed in an Appendix 3H filing to the ASX. The adjustment reflects a minor change in Orica’s issued capital structure and may be related to the expiry, lapse or settlement of incentive securities, signalling routine housekeeping in its equity-based remuneration arrangements rather than a fundamental shift in its capital management strategy.

The most recent analyst rating on (AU:ORI) stock is a Buy with a A$26.00 price target. To see the full list of analyst forecasts on Orica Limited stock, see the AU:ORI Stock Forecast page.

More about Orica Limited

Orica Limited, listed on the ASX under the code ORI, is a major Australian corporation operating as a public company with a broad shareholder base. It issues various classes of securities, including performance rights, as part of its capital and incentive structures for employees and executives.

Average Trading Volume: 1,778,775

Technical Sentiment Signal: Buy

Current Market Cap: A$12.15B

Find detailed analytics on ORI stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1